C-FMS POINT MUTATIONS IN ACUTE MYELOID-LEUKEMIA - FACT OR FICTION

被引:0
|
作者
SPRINGALL, F
OMARA, S
YI, SN
TODD, A
FORD, D
ILAND, H
机构
[1] ROYAL PRINCE ALFRED HOSP, KANEMATSU LABS, CAMPERDOWN, NSW 2050, AUSTRALIA
[2] PRINCE WALES HOSP, CELL BIOL UNIT, RANDWICK, NSW 2031, AUSTRALIA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Point mutations in codons 12,13, and 61 of N-ras have consistently been reported in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using a variety of techniques. Recently mutations in codons 301 and 969 of c-fms, preferentially involving TAT-to-TGT at codon 969, have also been identified in these disorders by allele specific oligonucleotide (ASO) hybridization. We have developed allele specific restriction analysis (ASRA) protocols for the detection of point mutations in the critical codons of these genes. ASRA involves enzymatic digestion of polymerase chain reaction (PCR)-induced restriction sites which are specific for normal but not mutant alleles. A total of 11 N-ras mutations were observed in 10 out of 46 AML patients, consistent with the reported frequency of N-ras mutations when alternative techniques of comparable sensitivity are used. In contrast, c-fms point mutations were not detected in a similar number of patients with AML, including 39 studied for mutations in both N-ras and c-fms, and this difference is statistically significant (p < 0.003). A more sensitive technique (ASRA + ASO hybridization) also failed to detect TAT-to-TGT substitutions at codon 969 in a subgroup of M4-AML patients considered to be at greatest risk of harboring c-fms mutations. This study suggests that c-fms mutations at codons 301 and 969 are not important in the pathogenesis of AML in the vast majority of patients.
引用
收藏
页码:978 / 985
页数:8
相关论文
共 50 条
  • [41] ACUTE MYELOID-LEUKEMIA IN ELDERLY PATIENTS
    GIUSTOLISI, R
    DIRAIMONDO, F
    GUGLIELMO, P
    CACCIOLA, RR
    PAFUMI, M
    HAEMATOLOGICA, 1984, 69 (02) : 240 - 242
  • [42] TREATMENT OF RESISTANT ACUTE MYELOID-LEUKEMIA
    SCHILLER, G
    BLOOD REVIEWS, 1991, 5 (04) : 220 - 226
  • [43] METABOLIC DISORDERS IN ACUTE MYELOID-LEUKEMIA
    AFZALMIR, M
    DELAMORE, IW
    BRITISH JOURNAL OF HAEMATOLOGY, 1978, 40 (01) : 79 - 92
  • [44] CLONAL REMISSIONS IN ACUTE MYELOID-LEUKEMIA
    BROWETT, PJ
    NELSON, J
    VANDEWATER, NS
    BLOOD, 1993, 82 (10) : A125 - A125
  • [45] TREATMENT OF ACUTE MYELOID-LEUKEMIA IN CHILDREN
    PATON, CM
    EKERT, H
    WATERS, KD
    MATTHEWS, RN
    TOOGOOD, IRG
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1982, 12 (02): : 143 - 146
  • [46] EXAGGERATED HYPOKALEMIA IN ACUTE MYELOID-LEUKEMIA
    ADAMS, PC
    WOODHOUSE, KW
    PARNHAM, A
    BRITISH MEDICAL JOURNAL, 1981, 283 (6284): : 139 - 139
  • [47] RAS GENES AND ACUTE MYELOID-LEUKEMIA
    TOKSOZ, D
    FARR, CJ
    MARSHALL, CJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1989, 71 (01) : 1 - 6
  • [48] ASPERGILLUS APPENDICITIS IN ACUTE MYELOID-LEUKEMIA
    ROGERS, S
    POTTER, MN
    SLADE, RR
    CLINICAL AND LABORATORY HAEMATOLOGY, 1990, 12 (04): : 471 - 476
  • [49] COLONIC OBSTRUCTION IN ACUTE MYELOID-LEUKEMIA
    KARATSIS, P
    FAROUK, M
    WYMAN, A
    SWEETLAND, HM
    ROGERS, K
    BRITISH JOURNAL OF SURGERY, 1993, 80 (12) : 1601 - 1601
  • [50] ENZYME MARKERS IN ACUTE MYELOID-LEUKEMIA
    SKOOG, L
    HAGERSTROM, T
    REIZENSTEIN, P
    OST, A
    SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 1986, 36 (01): : 25 - 32